Key result
Longer term mortality over 4 years for non-ST-segment-elevation acute coronary syndromes is about double that of ST-segment-elevation myocardial infarction, highlighting the need for optimal invasive therapy timing.
This review summarizes current strategies for patient selection and the optimal timing of invasive coronary angiography in the management of NSTEACS.
NSTEACS mortality disparity prioritizes invasive strategies; leaves open optimal timing for prospective trials.
While outcomes for ST-segment-elevation myocardial infarction has significantly decreased over the last years, patients presenting with non-ST-segment-elevation acute coronary syndromes (NSTEACS) still have a rather high mortality. Longer term mortality over 4 years is about double the mortality after a ST-segment-elevation myocardial infarction. The reason for the poorer prognosis is unclear but is very likely to be partially explained by the generally older age of NSTEACS patients. The optimal therapy for NSTEACS is less well defined. In this review, the authors specifically discuss the role of coronary angiography, how to decide which patient should undergo this procedure and whether there is an optimal time point. The review provides an up-to-date discussion about the best treatment strategies for NSTEACS.
No takes yet. Share an insight, caveat, or question.
Meier et al. (2013) conducted a review in Non-ST-segment-elevation acute coronary syndromes (NSTEACS). Coronary angiography / invasive therapy was evaluated. Longer term mortality over 4 years for non-ST-segment-elevation acute coronary syndromes is about double that of ST-segment-elevation myocardial infarction, highlighting the need for optimal invasive therapy timing.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: